JP7404256B2 - 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 - Google Patents

汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 Download PDF

Info

Publication number
JP7404256B2
JP7404256B2 JP2020547406A JP2020547406A JP7404256B2 JP 7404256 B2 JP7404256 B2 JP 7404256B2 JP 2020547406 A JP2020547406 A JP 2020547406A JP 2020547406 A JP2020547406 A JP 2020547406A JP 7404256 B2 JP7404256 B2 JP 7404256B2
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020547406A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019177888A5 (https=
JP2021517566A5 (https=
JP2021517566A (ja
Inventor
トーマ，クリスティアン
ラマー，ジャニン
パドゥラ，スティーヴン・ジョン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2021517566A publication Critical patent/JP2021517566A/ja
Publication of JPWO2019177888A5 publication Critical patent/JPWO2019177888A5/ja
Publication of JP2021517566A5 publication Critical patent/JP2021517566A5/ja
Priority to JP2023209816A priority Critical patent/JP7673168B2/ja
Application granted granted Critical
Publication of JP7404256B2 publication Critical patent/JP7404256B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2020547406A 2018-03-14 2019-03-08 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用 Active JP7404256B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023209816A JP7673168B2 (ja) 2018-03-14 2023-12-13 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862642641P 2018-03-14 2018-03-14
US62/642,641 2018-03-14
US201862683720P 2018-06-12 2018-06-12
US62/683,720 2018-06-12
US201862699274P 2018-07-17 2018-07-17
US62/699,274 2018-07-17
US201862729518P 2018-09-11 2018-09-11
US62/729,518 2018-09-11
PCT/US2019/021335 WO2019177888A1 (en) 2018-03-14 2019-03-08 Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023209816A Division JP7673168B2 (ja) 2018-03-14 2023-12-13 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用

Publications (4)

Publication Number Publication Date
JP2021517566A JP2021517566A (ja) 2021-07-26
JPWO2019177888A5 JPWO2019177888A5 (https=) 2023-03-23
JP2021517566A5 JP2021517566A5 (https=) 2023-03-23
JP7404256B2 true JP7404256B2 (ja) 2023-12-25

Family

ID=65904556

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020547406A Active JP7404256B2 (ja) 2018-03-14 2019-03-08 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
JP2023209816A Active JP7673168B2 (ja) 2018-03-14 2023-12-13 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023209816A Active JP7673168B2 (ja) 2018-03-14 2023-12-13 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用

Country Status (13)

Country Link
US (2) US20190284285A1 (https=)
EP (1) EP3765513A1 (https=)
JP (2) JP7404256B2 (https=)
KR (1) KR102768040B1 (https=)
CN (1) CN112272674A (https=)
AU (1) AU2019236105B2 (https=)
BR (1) BR112020016738A2 (https=)
CA (1) CA3093692A1 (https=)
CL (1) CL2020002342A1 (https=)
IL (1) IL277215B2 (https=)
MX (1) MX2020009544A (https=)
PH (1) PH12020551444A1 (https=)
WO (1) WO2019177888A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
EP3902604A1 (en) * 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) * 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
WO2022026829A1 (en) * 2020-07-30 2022-02-03 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for skin toxicity
JP2023536851A (ja) * 2020-07-30 2023-08-30 アナプティスバイオ インコーポレイティッド 魚鱗癬のための抗インターロイキン３６受容体（ｉｌ－３６ｒ）療法
CN121324515A (zh) * 2020-09-16 2026-01-13 上海市皮肤病医院 基于代谢组学的泛发性脓疱型银屑病诊断标志物及其应用
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
WO2022166977A1 (zh) * 2021-02-08 2022-08-11 上海普铭生物科技有限公司 抗人il-36r抗体及其应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
WO2022192531A2 (en) * 2021-03-12 2022-09-15 Boehringer Ingelheim International Gmbh Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
CN113274494B (zh) * 2021-06-07 2022-09-20 武汉生物制品研究所有限责任公司 一种抗SARS-CoV-2的重组全人源单克隆抗体的液体制剂
CN115327130A (zh) * 2022-07-25 2022-11-11 深圳市妇幼保健院 一种免疫生物标志物在制备小儿脓毒血症诊断试剂盒中的应用
CN115724975A (zh) * 2022-10-20 2023-03-03 江苏荃信生物医药股份有限公司 抗人白介素36受体单克隆抗体及其应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521933A (ja) 2005-12-28 2009-06-11 セントカー・インコーポレーテツド 乾癬および関連障害を評価および処置するためのマーカーおよび方法
JP2015500633A (ja) 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体
JP2016531123A (ja) 2013-08-15 2016-10-06 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
EP0999853B1 (en) 1997-06-13 2003-01-02 Genentech, Inc. Stabilized antibody formulation
ES2274574T3 (es) 1997-08-01 2007-05-16 Schering Corporation Proteinas de membrana celular de mamifero; reactivos relacionados.
US6416973B1 (en) 1997-08-01 2002-07-09 Schering Corporation Nucleic acids encoding mammalian cell membrane protein MDL-1
DE19733389C2 (de) 1997-08-01 1999-08-19 Deutsches Krebsforsch Mittel zur Expression und zum Nachweis eines ein HPOL-Epitop und ein Polypeptid enthaltenden Fusionspolypeptids
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1627927A3 (en) 2001-03-01 2006-06-07 Epigenomics AG Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the DNA
EP1556403A4 (en) 2002-10-03 2006-06-28 Large Scale Biology Corp MAKING MULTIMETER PROTEINS
CN1798575A (zh) 2003-04-04 2006-07-05 健泰科生物技术公司 高浓度抗体和蛋白制剂
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MX2009002456A (es) 2006-09-08 2009-03-20 Amgen Inc Variantes de la familia il-1.
CA2685015A1 (en) 2007-04-23 2008-11-06 Schering Corporation Anti-mdl-1 antibodies
US20100221252A1 (en) 2007-06-29 2010-09-02 Schering Corporation Mdl-1 uses
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
US9124378B2 (en) 2007-10-06 2015-09-01 The Nielsen Company (Us), Llc Gathering research data
US20110159011A1 (en) 2008-08-28 2011-06-30 Wyeth Llc Uses of il-22, il-17, and il-1 family cytokines in autoimmune diseases
WO2011026948A1 (en) 2009-09-03 2011-03-10 Ablynx N.V. Stable formulations of polypeptides and uses thereof
US20120121580A1 (en) 2009-07-28 2012-05-17 Merck Sharp & Dohme Corp. Methods for producing high concentration lyophilized pharmaceutical formulations
HRP20181598T1 (hr) 2010-06-03 2018-11-30 Abbvie Biotechnology Ltd Uporaba i pripravci za liječenje hidradenitis suppurativa (hs)
AU2013212587B2 (en) 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
DK3194583T3 (da) 2014-07-30 2021-12-20 Zumutor Biologics Inc Ikke-fucosyleret protein og fremgangsmåder dermed
CN105330740B (zh) 2014-07-30 2018-08-17 珠海市丽珠单抗生物技术有限公司 抗pd-1抗体及其应用
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
CN106470162B (zh) 2015-08-19 2019-06-25 中国移动通信集团公司 一种业务报文的组播方法及装置
JP6654773B2 (ja) 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
HRP20250951T1 (hr) 2015-12-30 2025-10-10 F. Hoffmann-La Roche Ag Formulacije sa smanjenom razgradnjom polisorbata
JP2020512344A (ja) 2017-03-27 2020-04-23 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体併用治療
CN107362351B (zh) 2017-09-04 2020-11-10 上海市儿童医院 Il-36r的拮抗剂在制备镇痛药物中的应用
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
AU2019234478A1 (en) 2018-03-14 2020-08-20 Boehringer Ingelheim International Gmbh Use of anti-IL36R antibodies for treatment of inflammatory bowel disease
MX2021000566A (es) 2018-07-16 2021-06-23 Regeneron Pharma Anticuerpos anti-il36r.
IL278267B2 (en) 2018-07-16 2025-02-01 Regeneron Pharma Non-human animal models of DITRA disease and their uses
EP3902604A1 (en) 2018-12-27 2021-11-03 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for treatment of palmoplantar pustulosis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
KR102708558B1 (ko) 2019-06-20 2024-09-24 삼성전자주식회사 수직형 메모리 장치
WO2021087245A1 (en) 2019-10-30 2021-05-06 The Texas A&M University System Protease switch for dual targets chimeric antigen receptor t cell therapy
EP4182022A1 (en) 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009521933A (ja) 2005-12-28 2009-06-11 セントカー・インコーポレーテツド 乾癬および関連障害を評価および処置するためのマーカーおよび方法
JP2015500633A (ja) 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体
JP2016531123A (ja) 2013-08-15 2016-10-06 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Investigative Dermatology，2013年，Vol.133，pp.2514-2521
MAbs，2017年，Vol.9，pp.1143-1154

Also Published As

Publication number Publication date
IL277215A (en) 2020-10-29
IL277215B1 (en) 2025-06-01
CL2020002342A1 (es) 2020-12-18
CN112272674A (zh) 2021-01-26
BR112020016738A2 (pt) 2020-12-15
AU2019236105B2 (en) 2025-07-31
JP2021517566A (ja) 2021-07-26
JP2024028951A (ja) 2024-03-05
AU2019236105A1 (en) 2020-08-27
WO2019177888A1 (en) 2019-09-19
IL277215B2 (en) 2025-10-01
CA3093692A1 (en) 2019-09-19
PH12020551444A1 (en) 2021-08-23
KR20200131871A (ko) 2020-11-24
US12503512B2 (en) 2025-12-23
US20190284285A1 (en) 2019-09-19
MX2020009544A (es) 2020-10-05
EP3765513A1 (en) 2021-01-20
US20210087285A1 (en) 2021-03-25
JP7673168B2 (ja) 2025-05-08
KR102768040B1 (ko) 2025-02-17

Similar Documents

Publication Publication Date Title
JP7404256B2 (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
WO2018102597A1 (en) Methods of treating inflammatory conditions
KR20140008305A (ko) Ｉｌ-１７ 길항제를 사용한 류마티스성 관절염의 치료 방법
CN104853774A (zh) Il-20拮抗剂用于治疗肝脏疾病
JP7662804B2 (ja) 汎発性膿疱性乾癬を処置する方法
US20220010022A1 (en) Anti-il-36r antibodies for the treatment of atopic dermatitis
EA046186B1 (ru) Применение антител к il-36r для лечения генерализованного пустулёзного псориаза
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
US20230416381A1 (en) Methods for treating or preventing acute respiratory distress syndrome
EA049580B1 (ru) Способы лечения гпп
CN116963776A (zh) 治疗gpp的方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220307

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20221223

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20230313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231114

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231213

R150 Certificate of patent or registration of utility model

Ref document number: 7404256

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150